Drugs / JX2105
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06537050 Comparator | Jul 2024 → Jan 2025 overdue | Parkinson disease | Zhejiang Jingxin Pharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JX2105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06537050 ↗ |
| Route | Oral | “Oral capsule” NCT06537050 ↗ |